Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other financing activities (2018 - 2025)

Voyager Therapeutics (VYGR) has disclosed Other financing activities for 8 consecutive years, with $434000.0 as the latest value for Q2 2025.

  • Quarterly Other financing activities fell 32.08% to $434000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Jun 2025, down 7.49% year-over-year, with the annual reading at $549000.0 for FY2025, 53.16% down from the prior year.
  • Other financing activities hit $434000.0 in Q2 2025 for Voyager Therapeutics, down from $639000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $639000.0 in Q2 2024 to a low of $313000.0 in Q2 2022.
  • Historically, Other financing activities has averaged $476800.0 across 5 years, with a median of $434000.0 in 2025.
  • Biggest five-year swings in Other financing activities: tumbled 46.03% in 2022 and later skyrocketed 52.87% in 2024.
  • Year by year, Other financing activities stood at $580000.0 in 2021, then crashed by 46.03% to $313000.0 in 2022, then soared by 33.55% to $418000.0 in 2023, then soared by 52.87% to $639000.0 in 2024, then plummeted by 32.08% to $434000.0 in 2025.
  • Business Quant data shows Other financing activities for VYGR at $434000.0 in Q2 2025, $639000.0 in Q2 2024, and $418000.0 in Q2 2023.